Correlation Between Viatris and Entrada Therapeutics

Can any of the company-specific risk be diversified away by investing in both Viatris and Entrada Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viatris and Entrada Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viatris and Entrada Therapeutics, you can compare the effects of market volatilities on Viatris and Entrada Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viatris with a short position of Entrada Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viatris and Entrada Therapeutics.

Diversification Opportunities for Viatris and Entrada Therapeutics

0.91

Correlation Coefficient

Viatris  Entrada Therapeutics

Almost no diversification

The 3 months correlation between Viatris and Entrada is 0.91. Overlapping area represents the amount of risk that can be diversified away by holding Viatris and Entrada Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entrada Therapeutics and Viatris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viatris are associated (or correlated) with Entrada Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entrada Therapeutics has no effect on the direction of Viatris i.e., Viatris and Entrada Therapeutics go up and down completely randomly.

Pair Corralation between Viatris and Entrada Therapeutics

Given the investment horizon of 90 days Viatris is expected to generate 0.38 times more return on investment than Entrada Therapeutics. However, Viatris is 2.66 times less risky than Entrada Therapeutics. It trades about -0.19 of its potential returns per unit of risk. Entrada Therapeutics is currently generating about -0.22 per unit of risk. If you would invest  1,309  in Viatris on November 29, 2024 and sell it today you would lose (185.00) from holding Viatris or give up 14.13% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Strong
Accuracy	100.0%
Values	Daily Returns

Viatris  vs.  Entrada Therapeutics

Viatris

Risk-Adjusted Performance

Very Weak

Over the last 90 days Viatris has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Entrada Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Entrada Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Viatris and Entrada Therapeutics

The main advantage of trading using opposite Viatris and Entrada Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viatris position performs unexpectedly, Entrada Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entrada Therapeutics will offset losses from the drop in Entrada Therapeutics' long position.

The idea behind Viatris and Entrada Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.